ACAD
NASDAQ · Biotechnology
Acadia Pharmaceuticals Inc
$22.09
+0.47 (+2.17%)
Financial Highlights (FY 2026)
Revenue
1.08B
Net Income
394.03M
Gross Margin
91.7%
Profit Margin
36.5%
Rev Growth
+13.8%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 91.7% | 91.7% | 38.8% | 38.8% |
| Operating Margin | 9.8% | 8.8% | 15.6% | 17.1% |
| Profit Margin | 36.5% | 34.7% | 16.3% | 14.5% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 1.08B | 948.62M | 1.03B | 1.09B |
| Gross Profit | 990.08M | 869.79M | 398.68M | 424.99M |
| Operating Income | 105.61M | 83.50M | 160.64M | 187.08M |
| Net Income | 394.03M | 311.54M | 167.73M | 158.84M |
| Gross Margin | 91.7% | 91.7% | 38.8% | 38.8% |
| Operating Margin | 9.8% | 8.8% | 15.6% | 17.1% |
| Profit Margin | 36.5% | 34.7% | 16.3% | 14.5% |
| Rev Growth | +13.8% | +13.8% | +10.0% | -1.3% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 1.70B | 1.80B |
| Total Equity | — | — | 1.87B | 1.74B |
| D/E Ratio | — | — | 0.91 | 1.03 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 106.51M | 88.89M | 233.13M | 238.00M |
| Free Cash Flow | — | — | 189.95M | 154.06M |